Predicting response to psychopharmacological treatment: Survey of recent results

Pharmacopsychiatry

Volumn 44, Issue 6, 2011, Pages 263-272

  Stassen, H ^a   Anghelescu, I G ^b   Angst, J ^a   Bker, H ^a   Lotscher K ^a   Rujescu, D ^c   Szegedi, A ^d   Scharfetter, C ^a  

^a UNIVERSITY HOSPITAL OF PSYCHIATRY   (Switzerland)

^b JANSSEN RESEARCH FOUNDATION   (Belgium)

^c UNIVERSITY OF MUNICH   (Germany)

^d MERCK RESEARCH LABORATORIES   (United States)

Author keywords

early onset; inflammatory processes; medical comorbidity; polypharmacy; severity at baseline; side effects; TDM

Indexed keywords

AMITRIPTYLINE; ANTIDEPRESSANT AGENT; FLUOXETINE; IMIPRAMINE; MIRTAZAPINE; MOCLOBEMIDE; NEUROLEPTIC AGENT; OXAPROTILINE; PAROXETINE; PLACEBO;

COMORBIDITY; DEPRESSION; DRUG MONITORING; HEALTH SURVEY; HUMAN; MAJOR CLINICAL STUDY; MAJOR DEPRESSION; MONOTHERAPY; POLYPHARMACY; PRIORITY JOURNAL; PSYCHOPHARMACOLOGY; PSYCHOPHARMACOTHERAPY; REVIEW; SCHIZOPHRENIA; TREATMENT DURATION; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT;

AGE FACTORS; ANTIDEPRESSIVE AGENTS; ANTIPSYCHOTIC AGENTS; CLINICAL TRIALS AS TOPIC; DEPRESSIVE DISORDER; DEPRESSIVE DISORDER, TREATMENT-RESISTANT; DISEASE PROGRESSION; DRUG MONITORING; HUMANS; IMMUNOGLOBULIN M; POLYPHARMACY; PSYCHOPHARMACOLOGY; TIME FACTORS; TREATMENT OUTCOME;

EID: 80053385071     PISSN: 01763679     EISSN: 14390795     Source Type: Journal    
DOI: 10.1055/s-0031-1286290     Document Type: Review

References (61)

1. Agid O, Kapur S, Arenovich T et al. Delayed-onset hypothesis of antipsychotic action: a hypothesis tested and rejected. Arch Gen Psychiatry: 2003; 60 1228 1235 (Pubitemid 37494076)
2. Agid O, Kapur S, Warrington L et al. Early onset of antipsychotic response in the treatment of acutely agitated patients with psychotic disorders. Schizophr Res: 2008; 102 241 248
3. Agid O, Seeman P, Kapur S. The delayed onset of antipsychotic action an idea whose time has come and gone. J Psychiatry Neurosci: 2006; 31 93 100
4. Altamura A C, Bassetti R, Cattaneo E et al. Some biological correlates of drug resistance in schizophrenia: a multidimensional approach. World J Biol Psychiatry: 2005; 6 02 23 30 (Pubitemid 41150413)
5. Anghelescu I G, Bridler R, Ltscher K et al. Polypharmacy in psychiatry: clinical implications. Psychopharmacology: 2011; in preparation
6. Bas S, Perneger T V, Seitz M et al. Diagnostic tests for rheumatoid arthritis: comparison of anti-cyclic citrullinated peptide antibodies, anti-keratin antibodies and IgM rheumatoid factors. Rheumatology: 2002; 41 809 814 (Pubitemid 34822965)
7. Berckel van B N, Bossong M G, Boellaard R et al. Microglia activation in recent-onset schizophrenia: A quantitative (R)-[11C]PK11195 positron emission tomography study. Biol Psychiatry: 2008; 64 820 822
8. Catena-DellOsso M, Bellantuono C, Consoli G et al. Inflammatory and neurodegenerative pathways in depression: a new avenue for antidepressant development? Curr Med Chem: 2011; 18 245 255
9. Dawood T, Lambert E A, Barton D A et al. Specific serotonin reuptake inhibition in major depressive disorder adversely affects novel markers of cardiac risk. Hypertens Res: 2007; 30 285 293 (Pubitemid 46779976)
10. De Berardis D, Conti C M, Serroni N et al. The effect of newer serotonin-noradrenalin antidepressants on cytokine production: a review of the current literature. Int J Immunopathol Pharmacol: 2010; 23 417 422
11. Ding K, Feng D, de Andrade M et al. Genomic regions that influence plasma levels of inflammatory markers in hypertensive sibships. J Hum Hypertens: 2008; 22 102 110
12. Eaton W W, Byrne M, Ewald H et al. Association of schizophrenia and autoimmune diseases: linkage of Danish national registers. Am J Psychiatry: 2006; 163 521 528 (Pubitemid 44469397)
13. Fan X, Goff D C, Henderson D C. Inflammation and schizophrenia. Expert Rev Neurother: 2007; 7 789 796 (Pubitemid 47037719)
14. Fornoni A, Ijaz A, Tejada T et al. Role of inflammation in diabetic nephropathy. Curr Diabetes Rev: 2008; 4 10 17 (Pubitemid 351216880)
15. Fournier J C, DeRubeis R J, Hollon S D et al. Antidepressant drug effects and depression severity: A patient-level meta-analysis. JAMA: 2010; 303 47 53
16. Hanson D R, Gottesman I I. Theories of schizophrenia: a genetic-inflammatory-vascular synthesis. BMC Med Genet: 2005; 6 7
17. Henkel V, Seemller F, Obermeier M et al. Does early improvement triggered by antidepressants predict response/remission? Analysis of data from a naturalistic study on a large sample of inpatients with major depression. J Affect Disord: 2009; 115 439 449
18. Hiemke C. Therapeutic drug monitoring in neuropsychopharmacology: does it hold its promises? Eur Arch Psychiatry Clin Neurosci: 2008; 258 01 21 27 (Pubitemid 351421448)
19. Hoffman B M, Babyak M A, Craighead W E et al. Exercise and Pharmacotherapy in Patients With Major Depression: One-Year Follow-Up of the SMILE Study. Psychosom Med: 2011; 73 127 133
20. Hoffmann K, Planitz C, Rschendorf F et al. A novel locus for arterial hypertension on chromosome 1p36 maps to a metabolic syndrome trait cluster in the Sorbs, a Slavic population isolate in Germany. J Hypertens: 2009; 27 983 990
21. Janssen D G, Caniato R N, Verster J C et al. A psychoneuroimmunological review on cytokines involved in antidepressant treatment response. Hum Psychopharmacol: 2010; 25 201 215
22. Jones A L, Mowry B J, Pender M P et al. Immune dysregulation and self-reactivity in schizophrenia: do some cases of schizophrenia have an autoimmune basis? Immunol Cell Biol: 2005; 83 9 17 (Pubitemid 40179396)
23. Kaestner F, Hettich M, Peters M et al. Different activation patterns of proinflammatory cytokines in melancholic and non-melancholic major depression are associated with HPA axis activity. J Affect Disord: 2005; 87 305 311 (Pubitemid 41039953)
24. Kemp D E, Ganocy S J, Brecher M et al. Clinical value of early partial symptomatic improvement in the prediction of response and remission during short-term treatment trials in 3369 subjects with bipolar I or II depression. J Affect Disord: 2011; 130 171 179
25. Khan A, Khan S R, Leventhal R M et al. Symptom reduction and suicide risk in patients treated with placebo in antidepressant clinical trials: a replication analysis of the Food and Drug Administration Database. Int J Neuropsychopharmacol: 2001; 4 113 118 (Pubitemid 32587377)
26. Khan A, Khan S R, Leventhal R M et al. Symptom reduction and suicide risk among patients treated with placebo in antipsychotic clinical trials: an analysis of the food and drug administration database. Am J Psychiatry: 2001; 158 1449 1454 (Pubitemid 32847244)
27. Khan A Y, Preskorn S H. Examining concentration-dependent toxicity of clozapine: role of therapeutic drug monitoring. J Psychiatr Pract: 2005; 11 289 301 (Pubitemid 41540224)
28. Kinon B J, Chen L, Ascher-Svanum H et al. Early response to antipsychotic drug therapy as a clinical marker of subsequent response in the treatment of schizophrenia. Neuropsychopharmacol: 2010; 35 581 590
29. Kinon B J, Chen L, Stauffer V L et al. Early onset of antipsychotic action in schizophrenia: evaluating the possibility of shorter acute efficacy trials. J Clin Psychopharmacol: 2010; 30 286 289
30. Kocsis J H, Gelenberg A J, Rothbaum B O et al. Cognitive behavioral analysis system of psychotherapy and brief supportive psychotherapy for augmentation of antidepressant nonresponse in chronic depression: the REVAMP Trial. Arch Gen Psychiatry: 2009; 66 1178 1188
31. Kurz T, Altmueller J, Strauch K et al. A genome-wide screen on the genetics of atopy in a multiethnic European population reveals a major atopy locus on chromosome 3q21.3. Allergy, Eur J of Allergy and Clinical Immunology: 2005; 60 192 199 (Pubitemid 40187473)
32. Lencz T, Malhotra A K. Pharmacogenetics of antipsychotic-induced side effects. Dialogues Clin Neurosci: 2009; 11 405 415
33. Lencz T, Robinson D G, Napolitano B et al. DRD2 promoter region variation predicts antipsychotic-induced weight gain in first episode schizophrenia. Pharmacogenet Genomics: 2010; 20 09 569 572
34. Leucht S, Arbter D, Engel R R et al. How effective are second-generation antipsychotic drugs? A meta-analysis of placebo-controlled trials. Mol Psychiatry: 2009; 14 429 447
35. Leucht S, Shamsi S A, Busch R et al. Predicting antipsychotic drug response replication and extension to six weeks in an international olanzapine study. Schizophr Res: 2008; 101 312 319
36. Levine S Z, Leucht S. Elaboration on the early-onset hypothesis of antipsychotic drug action: treatment response trajectories. Biol Psychiatry: 2010; 68 01 86 92
37. Ltscher K, Anghelescu I G, Braun S et al. Polypharmacy in psychiatry: clinical practice versus empirical evidence. Eur Neuropsychopharmacol: 2010; 20 03 378 379
38. Mller N, Myint A M, Schwarz M J. Inflammatory Biomarkers and Depression. Neurotox Res: 2011; 19 308 318
39. Mller N, Schwarz M J. The immune-mediated alteration of serotonin and glutamate: towards an integrated view of depression. Mol Psychiatry: 2007; 12 988 1000 (Pubitemid 350006207)
40. Mller N, Schwarz M J. A psychoneuroimmunological perspective to Emil Kraepelins dichotomy: schizophrenia and major depression as inflammatory CNS disorders. Eur Arch Psychiatry Clin Neurosci: 2008; 258 02 97 106 (Pubitemid 351758763)
41. Mller N, Schwarz M J. Immune System and Schizophrenia. Curr Immunol Rev: 2010; 6 213 220
42. Papakostas G I, Perlis R H, Scalia M J et al. A meta-analysis of early sustained response rates between antidepressants and placebo for the treatment of major depressive disorder. J Clin Psychopharmacol: 2006; 26 56 60 (Pubitemid 43167092)
43. Plenge R M, Seielstad M, Padyukov L et al. TRAF1-C5 as a risk locus for rheumatoid arthritis a genomewide study. N Engl J Med: 2007; 357 1199 1209 (Pubitemid 47443179)
44. Posternak M A, Zimmerman M. Is there a delay in the antidepressant effect? A meta-analysis. J Clin Psychiatry: 2005; 66 02 148 158 (Pubitemid 40314320)
45. Prapotnik M, Waschgler R, Knig P et al. Therapeutic drug monitoring of trazodone: are there pharmacokinetic interactions involving citalopram and fluoxetine? Int J Clin Pharmacol Ther: 2004; 42 120 124 (Pubitemid 38219924)
46. Savoia C, Schiffrin E L. Reduction of C-reactive protein and the use of anti-hypertensives. Vasc Health Risk Manag: 2007; 3 975 983
47. Shankar A, Li J. Positive association between high-sensitivity C-reactive protein level and diabetes mellitus among US non-Hispanic black adults. Exp Clin Endocrinol Diabetes: 2008; 116 455 460
48. Shelton R C, Miller A H. Eating ourselves to death (and despair): the contribution of adiposity and inflammation to depression. Prog Neurobiol: 2010; 91 275 299
49. Sicard M N, Zai C C, Tiwari A K et al. Polymorphisms of the HTR2C gene and antipsychotic-induced weight gain: an update and meta-analysis. Pharmacogenomics: 2010; 11 1561 1571
50. Stassen H H, Angst J, Hell D et al. Is there a common resilience mechanism underlying antidepressant drug response? Evidence from 2848 patients. J Clin Psychiatry: 2007; 68 1195 1205 (Pubitemid 47395621)
51. Stassen H H, Kuny S, Hell D. The speech analysis approach to determining onset of improvement under antidepressants. Eur Neuropsychopharmacology: 1998; 8 04 303 310 (Pubitemid 28557025)
52. Stassen H H, Szegedi A, Scharfetter C. Modeling Activation of Inflammatory Response System. A Molecular-Genetic Neural Network Analysis. BMC Proceedings: 2007; 1 01 S61 16
53. Stolk P, Ten Berg M J, Hemels M E et al. Meta-analysis of placebo rates in major depressive disorder trials. Ann Pharmacother: 2003; 37 1891 1899 (Pubitemid 37466590)
54. Strous R D, Shoenfeld Y. Schizophrenia, autoimmunity and immune system dysregulation: a comprehensive model updated and revisited. J Autoimmun: 2006; 27 02 71 80 (Pubitemid 44528264)
55. Szegedi A, Jansen W T, Van Willigenburg A P et al. Early improvement as a predictor of treatment outcome in patients with major depressive disorder: Why the first 2 weeks really matter evidence from 6562 patients. J Clin Psychiatry: 2009; 70 344 353
56. Tadic A, Rujescu D, Dahmen N et al. Association Analysis between Variants of the Interleukin-1 and the Interleukin-1 Receptor Antagonist Gene and Antidepressant Treatment Response in Major Depression. Neuropsychiatr Dis Treat: 2008; 4 269 276 (Pubitemid 351460964)
57. Tamura R N, Faries D E, Feng J. Comparing time to onset of response in antidepressant clinical trials using the cure model and the Cramer-von Mises test. Stat Med: 2000; 19 2169 2184 (Pubitemid 30641282)
58. Tiwari A K, Zai C C, Likhodi O et al. A common polymorphism in the cannabinoid receptor 1 (CNR1) gene is associated with antipsychotic-induced weight gain in Schizophrenia. Neuropsychopharmacol: 2010; 35 1315 1324
59. Tsai T C, Lu J H, Chen S J et al. Soluble interleukin-10 and transforming growth factor-beta in children with acute exacerbation of allergic asthma. J Asthma: 2009; 46 21 24
60. Waldschmitt C, Vogel F, Pfuhlmann B et al. Duloxetine serum concentrations and clinical effects. Data from a therapeutic drug monitoring (TDM) survey. Pharmacopsychiatry: 2009; 42 05 189 193
61. Warrier M R, Hershey G K. Asthma genetics: personalizing medicine. J Asthma: 2008; 45 04 257 264 (Pubitemid 351630915)